Cancer Therapeutics ups stake in NanoTherapies

Cancer Therapeutics, has signed a letter of intent to acquire another 26 percent interest in NanoTherapies, giving Cancer Therapeutics a total of 51 percent and controlling interest of NanoTherapies. Release

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.